POLLUX — Daratumumab Plus Lenalidomide-Dexamethasone Versus Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma (POLLUX)

Phase 3 · 2016 · Multiple Myeloma

Design

Randomized, open-label trial of daratumumab plus lenalidomide-dexamethasone vs Rd until progression.

Population

Relapsed or refractory multiple myeloma after at least one prior line of therapy.

Primary Endpoint

progression-free survival (PFS)

Key Result

At interim, median PFS not reached vs 18.4 mo (HR 0.37); long-term analysis showed PFS 45.0 vs 17.5 mo (HR 0.44).

Guideline Impact

NCCN-listed daratumumab-Rd for relapsed/refractory multiple myeloma